Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

60.69 (USD) • At close November 8, 2024
Bedrijfsnaam Crinetics Pharmaceuticals, Inc.
Symbool CRNX
Munteenheid USD
Prijs 60.69
Beurswaarde 5,464,260,564
Dividendpercentage 0%
52-weken bereik 25.75 - 60.92
Industrie Biotechnology
Sector Healthcare
CEO Dr. R. Scott Struthers Ph.D.
Website https://www.crinetics.com

An error occurred while fetching data.

Over Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of

Vergelijkbare Aandelen

Veru Inc. logo

Veru Inc.

VERU

0.732 USD

MannKind Corporation logo

MannKind Corporation

MNKD

7.345 USD

Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

LYEL

1.22 USD

NeoGenomics, Inc. logo

NeoGenomics, Inc.

NEO

15.77 USD

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

104.25 USD

Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

AXSM

90.07 USD

Cassava Sciences, Inc. logo

Cassava Sciences, Inc.

SAVA

26.95 USD

Silk Road Medical, Inc logo

Silk Road Medical, Inc

SILK

27.49 USD

Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

ARQT

10.82 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)